ESSA Pharma (NASDAQ:EPIX) Releases Earnings Results, Beats Expectations By $0.05 EPS

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) announced its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05, Zacks reports.

ESSA Pharma Stock Performance

Shares of NASDAQ:EPIX opened at $1.61 on Thursday. ESSA Pharma has a 52 week low of $1.40 and a 52 week high of $11.67. The company has a market cap of $71.43 million, a PE ratio of -2.60 and a beta of 1.62. The firm has a 50 day simple moving average of $3.01 and a 200 day simple moving average of $4.61.

Analyst Upgrades and Downgrades

EPIX has been the subject of a number of research analyst reports. Jefferies Financial Group downgraded shares of ESSA Pharma from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Piper Sandler lowered shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $15.00 to $2.00 in a research report on Monday, November 4th. Finally, Oppenheimer lowered ESSA Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th.

Insider Buying and Selling at ESSA Pharma

In other news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $1.53, for a total value of $12,055,761.99. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 14.70% of the company’s stock.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.